$AGIO
Agios Pharmaceuticals Inc

2015 Q4 Form 10-Q Financial Statement

#000119312515370225 Filed on November 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $6.218M $5.480M $33.90M
YoY Change -57.52% -83.83% 440.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.18M $9.930M $5.170M
YoY Change 56.62% 92.07% 104.35%
% of Gross Profit
Research & Development $36.93M $36.03M $25.53M
YoY Change 5.94% 41.14% 72.44%
% of Gross Profit
Depreciation & Amortization $1.100M $1.000M $300.0K
YoY Change 175.0% 233.33% -25.0%
% of Gross Profit
Operating Expenses $47.12M $45.96M $30.69M
YoY Change 13.93% 49.73% 77.03%
Operating Profit -$40.90M -$40.48M $3.208M
YoY Change 53.02% -1361.69% -128.98%
Interest Expense $280.0K $220.0K $50.00K
YoY Change 211.11% 340.0% 400.0%
% of Operating Profit 1.56%
Other Income/Expense, Net
YoY Change
Pretax Income -$40.62M -$40.26M $3.256M
YoY Change 52.48% -1336.39% -129.45%
Income Tax $0.00 $0.00 -$448.0K
% Of Pretax Income -13.76%
Net Earnings -$40.62M -$40.26M $3.704M
YoY Change 52.34% -1186.85% -133.14%
Net Earnings / Revenue -653.26% -734.62% 10.93%
Basic Earnings Per Share -$1.07 $0.11
Diluted Earnings Per Share -$1.079M -$1.07 $0.10
COMMON SHARES
Basic Shares Outstanding 37.64M shares 37.51M shares 34.50M shares
Diluted Shares Outstanding 37.51M shares 36.59M shares

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $317.0M $352.4M $220.0M
YoY Change -7.33% 60.19% 12.81%
Cash & Equivalents $71.76M $80.05M $70.05M
Short-Term Investments $245.2M $272.3M $149.9M
Other Short-Term Assets $8.700M $7.200M $8.800M
YoY Change 1.16% -18.18% 131.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $337.3M $371.7M $247.6M
YoY Change -6.18% 50.13% 24.52%
LONG-TERM ASSETS
Property, Plant & Equipment $23.22M $21.13M $3.677M
YoY Change 263.61% 474.57% 3.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $58.90M $55.60M $17.90M
YoY Change -53.03% 210.61% 33.58%
Other Assets $611.0K $678.0K $454.0K
YoY Change 3.56% 49.34% 4027.27%
Total Long-Term Assets $82.74M $77.43M $22.05M
YoY Change -37.49% 251.17% 8.87%
TOTAL ASSETS
Total Short-Term Assets $337.3M $371.7M $247.6M
Total Long-Term Assets $82.74M $77.43M $22.05M
Total Assets $420.1M $449.1M $269.6M
YoY Change -14.6% 66.57% 23.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.75M $8.971M $6.225M
YoY Change 33.26% 44.11% 190.89%
Accrued Expenses $16.00M $15.99M $10.00M
YoY Change 14.09% 59.79% 109.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $52.89M $49.76M $35.08M
YoY Change -13.42% 41.82% -6.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $22.10M $23.70M $26.80M
YoY Change 245.31% -11.57% 10129.01%
Total Long-Term Liabilities $22.10M $23.70M $26.80M
YoY Change 245.31% -11.57% 10129.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $52.89M $49.76M $35.08M
Total Long-Term Liabilities $22.10M $23.70M $26.80M
Total Liabilities $74.90M $73.40M $61.90M
YoY Change 10.96% 18.58% 64.46%
SHAREHOLDERS EQUITY
Retained Earnings -$284.7M -$244.1M -$140.3M
YoY Change 70.52% 73.97% 38.81%
Common Stock $630.1M $619.5M $348.0M
YoY Change 6.55% 78.02% 42.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $345.1M $375.7M $207.7M
YoY Change
Total Liabilities & Shareholders Equity $420.1M $449.1M $269.6M
YoY Change -14.6% 66.57% 23.07%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$40.62M -$40.26M $3.704M
YoY Change 52.34% -1186.85% -133.14%
Depreciation, Depletion And Amortization $1.100M $1.000M $300.0K
YoY Change 175.0% 233.33% -25.0%
Cash From Operating Activities -$30.50M -$24.80M -$23.50M
YoY Change 291.03% 5.53% 56.67%
INVESTING ACTIVITIES
Capital Expenditures -$2.200M -$3.300M -$600.0K
YoY Change 46.67% 450.0% 500.0%
Acquisitions
YoY Change
Other Investing Activities $23.20M $33.40M -$14.50M
YoY Change -108.12% -330.34% -82.01%
Cash From Investing Activities $20.90M $30.20M -$15.10M
YoY Change -107.27% -300.0% -81.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.300M 2.200M 400.0K
YoY Change -99.46% 450.0% -99.68%
NET CHANGE
Cash From Operating Activities -30.50M -24.80M -23.50M
Cash From Investing Activities 20.90M 30.20M -15.10M
Cash From Financing Activities 1.300M 2.200M 400.0K
Net Change In Cash -8.300M 7.600M -38.20M
YoY Change -85.18% -119.9% -234.04%
FREE CASH FLOW
Cash From Operating Activities -$30.50M -$24.80M -$23.50M
Capital Expenditures -$2.200M -$3.300M -$600.0K
Free Cash Flow -$28.30M -$21.50M -$22.90M
YoY Change 349.21% -6.11% 53.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37640637 shares
CY2014Q2 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
-700000
CY2014Q3 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
-400000
CY2014Q3 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
-400000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70049000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4650549 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
43.98
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37605377 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1891959 shares
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
43.89
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
12 Securities
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37605377 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.51
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4321479 shares
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
619451000
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
356000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5416000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
375657000
CY2015Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2015Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1002000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
225000
CY2015Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
2150000
CY2015Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17433000
CY2015Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
226000
CY2015Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
22650000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8971000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15985000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-244057000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
449086000
CY2015Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6240000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
38000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
49756000
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
115558000
CY2015Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
327938000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
678000
CY2015Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
163459000
CY2015Q3 us-gaap Assets
Assets
449086000
CY2015Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
2992000
CY2015Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
9600000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21127000
CY2015Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
55621000
CY2015Q3 us-gaap Contracts Receivable Claims And Uncertain Amounts
ContractsReceivableClaimsAndUncertainAmounts
9100000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
371660000
CY2015Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
272317000
CY2015Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
9078000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7225000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80048000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
175735000
CY2015Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2015Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
327713000
CY2015Q3 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
9211000
CY2013Q4 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
-700000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71560000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3805420 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.19
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37100513 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
92 Securities
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37100513 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
591334000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
448000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5689000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
424366000
CY2014Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2014Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
549000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-57000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
310000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3724000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
35686000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11067000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14026000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166948000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
491904000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2725000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
61089000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
453416000
CY2014Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3841000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
590000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
107000
CY2014Q4 us-gaap Assets
Assets
491904000
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
2334000
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
236900000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6386000
CY2014Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
125382000
CY2014Q4 us-gaap Contracts Receivable Claims And Uncertain Amounts
ContractsReceivableClaimsAndUncertainAmounts
6500000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
359546000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
328034000
CY2014Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
6492000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4814000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14031000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
360935000
CY2014Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
453473000
CY2014Q4 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
7340000
agio Collaboration Revenue
CollaborationRevenue
36600000
CY2015Q2 agio Revenue Recognized On Extended Agreement
RevenueRecognizedOnExtendedAgreement
700000
agio Collaboration Revenue
CollaborationRevenue
16300000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-51578000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0183 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3829961 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8477 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33176801 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33176801 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
50722000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
727000
us-gaap Net Income Loss
NetIncomeLoss
-26840000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26840000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-80000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2756000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27406000
us-gaap Income Taxes Paid
IncomeTaxesPaid
5958000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-412000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
37000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26803000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
18283000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27288000
us-gaap Investment Income Interest
InvestmentIncomeInterest
118000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
197000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
215383000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-448000
us-gaap Share Based Compensation
ShareBasedCompensation
6778000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12439000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1511000
us-gaap Operating Expenses
OperatingExpenses
78128000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-46034000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
96101000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65509000
us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
571000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1416000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6778000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3414000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12619000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5303000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
169505000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2354000
us-gaap Depreciation
Depreciation
1005000
agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
184000
agio Proceeds From Payments Of Issuance Of Common Stock Commissions And Offering Costs
ProceedsFromPaymentsOfIssuanceOfCommonStockCommissionsAndOfferingCosts
94685000
agio Vesting Of Restricted Stock Value Increase Decrease
VestingOfRestrictedStockValueIncreaseDecrease
-7000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-46420000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y15D
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0171 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
46283 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4667313 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001439222
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M5D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
43.94
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6976 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
107.11
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS INC
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37351493 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1360606 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.76
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37351493 shares
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
469194 shares
dei Trading Symbol
TradingSymbol
AGIO
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M17D
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
52901000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17978000
us-gaap Net Income Loss
NetIncomeLoss
-77110000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-77110000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-15549000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2317000
us-gaap Operating Income Loss
OperatingIncomeLoss
-77802000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-431000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
659000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
282000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76828000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
2585000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-77110000
us-gaap Investment Income Interest
InvestmentIncomeInterest
692000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1080000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
218657000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Share Based Compensation
ShareBasedCompensation
22610000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9522000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
66017000
us-gaap Operating Expenses
OperatingExpenses
130703000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
107351000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5086000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
104894000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5293000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22610000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2469000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25809000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3841000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
343986000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1324000
us-gaap Depreciation
Depreciation
2197000
agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
200000
agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
agio Reimbursement Of Research And Development Related Party Cost
ReimbursementOfResearchAndDevelopmentRelatedPartyCost
16729000
agio Proceeds From Payments Of Issuance Of Common Stock Commissions And Offering Costs
ProceedsFromPaymentsOfIssuanceOfCommonStockCommissionsAndOfferingCosts
-207000
agio Vesting Of Restricted Stock Value Increase Decrease
VestingOfRestrictedStockValueIncreaseDecrease
-6000
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
6000000
CY2014Q1 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
1500000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M29D
CY2014 agio Initial Agreement Period
InitialAgreementPeriod
P5Y
CY2014 agio Receipt Due To Agreement Amendment
ReceiptDueToAgreementAmendment
20000000
CY2014 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2016-04
CY2014 agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
CY2014 agio Extended Agreement Period
ExtendedAgreementPeriod
P6Y
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0195 pure
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1484917 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7889 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36592683 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34495076 shares
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2014Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
33900000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
3704000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3704000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3208000
CY2014Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
39000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3743000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3256000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
48000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-448000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
30692000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25526000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2892000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5166000
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y22D
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0173 pure
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4667313 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6776 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37507298 shares
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37507298 shares
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2015Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
5480000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-40257000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40257000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-40475000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40254000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40257000
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
218000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
45955000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36028000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9372000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9927000
CY2015Q3 agio Reimbursement Of Research And Development Related Party Cost
ReimbursementOfResearchAndDevelopmentRelatedPartyCost
7817000

Files In Submission

Name View Source Status
0001193125-15-370225-index-headers.html Edgar Link pending
0001193125-15-370225-index.html Edgar Link pending
0001193125-15-370225.txt Edgar Link pending
0001193125-15-370225-xbrl.zip Edgar Link pending
agio-20150930.xml Edgar Link completed
agio-20150930.xsd Edgar Link pending
agio-20150930_cal.xml Edgar Link unprocessable
agio-20150930_def.xml Edgar Link unprocessable
agio-20150930_lab.xml Edgar Link unprocessable
agio-20150930_pre.xml Edgar Link unprocessable
d53155d10q.htm Edgar Link pending
d53155dex311.htm Edgar Link pending
d53155dex312.htm Edgar Link pending
d53155dex321.htm Edgar Link pending
d53155dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending